At PCR, Drug-Eluting Stents From Asia, But At What Cost?
Executive Summary
No one would place drug-eluting stents among the hot technologies showcased at this year’s EuroPCR, not with all of the buzz around renal denervation, percutaneous valves, and bioabsorbable stents and scaffolds. But an early morning session on DES from India and China underscored how the technology debate is changing in a world of cost constraints and emerging markets, particularly for mature categories.
You may also be interested in...
EuroPCR 2013: The Calm After The Technology Storm
For the past several years, TAVI and renal denervation have dominated EuroPCR, the largest interventional cardiology conference in Europe. This year’s conference in Paris in May was more balanced, leaving room for interest in bioresorbable stents and mitral valves.
EuroPCR 2013: The Calm After The Technology Storm
For the past several years, TAVI and renal denervation have dominated EuroPCR, the largest interventional cardiology conference in Europe. This year’s conference in Paris in May was a bit more balanced, leaving room for interest in bioresorbable stents and mitral valves.
EuroPCR 2013: The Calm After The Technology Storm
For the past several years, TAVI and renal denervation have dominated EuroPCR, the largest interventional cardiology conference in Europe. This year’s conference in Paris in May was a bit more balanced, leaving room for interest in bioresorbable stents and mitral valves.